Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Pictilisib
Cat. No.:
OB0225LY-0349
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Pictilisib is a selective PI3K inhibitor with antitumor activity.
Synonym:
RG7321; GDC-0941; 957054-30-7; 4-(2-(1H-Indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thieno[3,2-d]pyrimidin-4-yl)morpholine; 2-(1H-Indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine; Thieno(3,2-d)pyrimidine, 2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)-1-piperazinyl]methyl)-4-(4-morpholinyl)-
CAS No.:
957054-30-7
Compound CID:
17755052
Formula:
C23H27N7O3S2
Formula Weight:
513.64
Specification
Relative Density:
1.53 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Pictilisib can be used in tumor biology studies or play an important role in PI3K/Akt pathway studies.
Library Information
Targets:
PI3K family
Receptors:
p110α; p110β; p110γ; p110δ
Pathways:
PI3K/Akt/mTOR signaling; Autophagy; Apoptosis
Plate Number:
AOCL-5
Plate Location:
e3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
41 mg/mL; 79.8 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.153
HBA_Count:
6
HBD_Count:
1
Rotatable Bond:
5
